Interferon-α2a and Vogt-Koyanagi-Harada disease: A double-edged sword?

International Ophthalmology

Volumn 27, Issue 2-3, 2007, Pages 211-215

  Touitou, Valerie ^a   Sene, Damien ^a   Fardeau, Christine ^a   Boutin, Thi Huong Du ^a   Duhaut, Pierre ^b   Piette, Jean Charles ^a   LeHoang, Phuc ^a   Cacoub, Patrice ^a   Bodaghi, Bahram ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b North Hospital   (France)

Author keywords

Hepatitis C virus infection; Interferon 2a; Refractory uveitis; Vogt Koyanagi Harada disease

Indexed keywords

ALPHA2A INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; PARACETAMOL; PREDNISONE; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; ASTHENIA; BIOMICROSCOPY; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; DRUG DEPENDENCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG RESPONSE; EYE FUNDUS; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HEADACHE; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; LOW DRUG DOSE; LUMBAR PUNCTURE; MENINGITIS; MYALGIA; OPHTHALMOSCOPY; OPTIC DISK; RELAPSE; RETINA DETACHMENT; RETINA MACULA EDEMA; RISK BENEFIT ANALYSIS; SLIT LAMP; UVEITIS; VISUAL ACUITY; VISUAL IMPAIRMENT; VITILIGO; VOGT KOYANAGI SYNDROME; DRUG COMBINATION; MENINGOENCEPHALITIS; MIDDLE AGED; RECURRENT DISEASE;

ADULT; ANTIVIRAL AGENTS; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON ALFA-2A; METHYLPREDNISOLONE; MIDDLE AGED; RECURRENCE; UVEOMENINGOENCEPHALITIC SYNDROME;

EID: 34250358302     PISSN: 01655701     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10792-007-9040-2     Document Type: Article

References (35)

1. Wechsler B, Bodaghi B, Huong DL et al (2000) Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behcet's disease. Ocul Immunol Inflamm 8:293-301
2. Pivetti-Pezzi P, Accorinti M, Pirraglia MP et al (1997) Interferon alpha for ocular Behcet's disease. Acta Ophthalmol Scand 75:720-722
3. Okada AA (2000) Drug therapy in Behcet's disease. Ocul Immunol Inflamm 8:85-91 (in press)
4. Bodaghi B, Gendron G, Wechsler B et al (2006) Efficacy of interferon alpha in the treatment of refractory and sight-threatening uveitis: A retrospective monocentric study of 45 patients. Br J Ophthalmol (in press)
5. Deuter CM, Koetter I, Guenaydin I et al (2006) Interferon alfa-2a: A new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina 26:786-791
6. Brasnu E, Wechsler B, Bron A et al (2005) Efficacy of interferon-alpha for the treatment of Kaposi's sarcoma herpesvirus-associated uveitis. Am J Ophthalmol 140:746-748
7. Matsuo T, Takabatake R (2002) Multiple sclerosis-like disease secondary to alpha interferon. Ocul Immunol Inflamm 10:299-304
8. Perlemuter G, Bodaghi B, Le Hoang P et al (2002) Visual loss during interferon-alpha therapy in hepatitis C virus infection. J Hepatol 37:701-702
9. Yamada H, Mizobuchi K, Isogai Y (1994) Acute onset of ocular complications with interferon. Lancet 343:914
10. Sylvestre DL, Disston AR, Bui DP (2003) Vogt-Koyanagi-Harada disease associated with interferon alpha-2b/ribavirin combination therapy. J Viral Hepat 10:467-470
11. Touitou V, Bodaghi B, Cassoux N et al (2005) Vogt-Koyanagi-Harada disease in patients with chronic hepatitis C. Am J Ophthalmol 140:949-952
12. Kasahara A, Hiraide A, Tomita N et al (2004) Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C. J Gastroenterol 39:1106-1109
13. Arnaud P (2002) [The interferons: Pharmacology, mechanism of action, tolerance and side effects]. Rev Med Interne 23(Suppl 4):449s-458s
14. Sanda C, Weitzel P, Tsukahara T et al (2006) Differential gene induction by type I and type II interferons and their combination. J Interferon Cytokine Res 26:462-472
15. Okada AA, Keino H, Suzuki J et al (1998) Kinetics of intraocular cytokines in the suppression of experimental autoimmune uveoretinitis by type I IFN. Int Immunol 10:1917-1922
16. Okada AA, Keino H, Fukai T et al (1998) Effect of type I interferon on experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm 6:215-226
17. Stubiger N, Crane IJ, Kotter I et al (2003) Interferon alpha 2a in IRPB-derived peptide-induced EAU-part I. Adv Exp Med Biol 528:537-540
18. Treusch M, Stubiger N, Vonthein R et al (2003) Influence of interferon-alpha on lymphocyte subpopulations in Behcet's disease. Adv Exp Med Biol 528:533-535
19. Treusch M, Vonthein R, Baur M et al (2004) Influence of human recombinant interferon-alpha2a (rhIFN-alpha2a) on altered lymphocyte subpopulations and monocytes in Behcet's disease. Rheumatology (Oxford) 43:1275-1282
20. Kotter I, Gunaydin I, Treusch M et al (2003) The use of interferon-alpha in Behcet's disease-review of the literature and possible mechanisms of action. Adv Exp Med Biol 528:503-509
21. Pellicano R, Smedile A, Peyre S et al (2005) Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: The hepatologist's view. Minerva Gastroenterol Dietol 51:55-61
22. Selmi C, Lleo A, Zuin M et al (2006) Interferon alpha and its contribution to autoimmunity. Curr Opin Investig Drugs 7:451-456
23. Oshima Y, Harino S, Hara Y et al (1996) Indocyanine green angiographic findings in Vogt-Koyanagi-Harada disease. Am J Ophthalmol 122:58-66
24. Harada T, Kanbara Y, Takeuchi T et al (1997) Exploration of Vogt-Koyanagi-Harada syndrome by infrared choroidal angiography with indocyanine green. Eur J Ophthalmol 7:163-170
25. Bouchenaki N, Herbort CP (2001) The contribution of indocyanine green angiography to the appraisal and management of Vogt-Koyanagi-Harada disease. Ophthalmology 108:54-64
26. Gupta R, Singh S, Tang R et al (2002) Anterior ischemic optic neuropathy caused by interferon alpha therapy. Am J Med 112:683-684
27. Vardizer Y, Linhart Y, Loewenstein A et al (2003) Interferon-alpha-associated bilateral simultaneous ischemic optic neuropathy. J Neuroophthalmol 23:256-259
28. Norcia F, Di Maria A, Prandini F et al (1999) Natural interferon therapy: Optic nerve ischemic damage? Ophthalmologica 213:339-340
29. Purvin VA (1995) Anterior ischemic optic neuropathy secondary to interferon alfa. Arch Ophthalmol 113:1041-1044
30. van der Eijk AA, Vrolijk JM, Haagmans BL (2006) Antibodies neutralizing peginterferon alfa during retreatment of hepatitis C. N Engl J Med 354:1323-1324
31. Haria M, Benfield P (1995) Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis. Drugs 50:873-896
32. Leroy V, Baud M, de Traversay C et al (1998) Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C. J Hepatol 28:375-381
33. Antonelli G, Simeoni E, Bagnato F et al (1999) Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. J Neurol Sci 168:131-136
34. Antonelli G, Bagnato F, Pozzilli C et al (1998) Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a. J Interferon Cytokine Res 18:345-350
35. Ross C, Engler CB, Sander B et al (2002) IFN-alpha antibodies in patients with age-related macular degeneration treated with recombinant human IFN-alpha2a. J Interferon Cytokine Res 22:421-426